New Drugs and Regimens – Funding

TB MAC is pleased to announce the first funding award from meeting 3 “Modelling to support the rational introduction of new drugs and regimens”. Kathryn Schnippel (Health Economics and Epidemiology Research Office, University of Witwatersand) has been awarded funds for “Assessing the health outcomes and economic consequences of different strategies for scale-up of novel regimens”.
The second of TB MAC funding awards from this meeting has been awarded to the William Davidson Institute at the University of Michigan and Imperial College London, for the research question “Modelling to understand the epidemiological impact and market impact of harmonized regimes for MDR-TB”. The modelling approach will determine optimal treatment regimes for drug resistant TB for specific epidemiological, DST scale up and socio-economic contexts, with a focus on the high MDR-burden country of India.